Anzeige
Meldung des Tages: Wenn Lieferketten brechen: Dieses Metall könnte zum nächsten Engpass werden

Nicox News

Aktie
WKN:  A143G8 ISIN:  FR0013018124 US-Symbol:  NICXF Branche:  Biotechnologie Land:  Frankreich
0,401 €
+0,0335 €
+9,12%
15:32:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
17,62 Mio. €
Streubesitz
85,41%
KGV
-0,62
Index-Zuordnung
-

Nicox News

24.02.26 - GlobeNewswire
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting February 24, 2026 – ...
16.02.26 - GlobeNewswire
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 U.S. NDA submission on track for summer 2026 Nicox to receive milestone ...
10.02.26 - GlobeNewswire
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 February 10, 2026 – release at 7:30 am Sophia ...
20.01.26 - GlobeNewswire
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, ...
05.01.26 - GlobeNewswire
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
Press Release
16.12.25 - GlobeNewswire
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
Press Release Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required ...
23.10.25 - GlobeNewswire
Nicox Provides First Half 2025 Financial Results
Press Release Nicox Provides First Half 2025 Financial Results  New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and China Company believes ...
02.10.25 - GlobeNewswire
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-​planned analysis of ...
04.09.25 - GlobeNewswire
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026 NCX ...
26.08.25 - GlobeNewswire
Nicox Announces Shareholder Q&A Webpage Available
Press Release Nicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris ...
21.08.25 - GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 ...
08.08.25 - GlobeNewswire
Nicox Extends Existing Flexible Equity Financing
Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory ...
05.08.25 - GlobeNewswire
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for ...
17.07.25 - GlobeNewswire
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 ...
30.06.25 - GlobeNewswire
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-​August to mid-​September 2025 New Drug Application ...
27.05.25 - GlobeNewswire
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese ...
14.05.25 - GlobeNewswire
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial  Several aqueous humor parameters stimulated by nitric oxide were statistically ...
30.04.25 - GlobeNewswire
Nicox Provides Full Year 2024 Financial Results
Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024  Exceptional income of €13.7 million following the transfer of ...

Newssuche

Videos

newspaper
23.03.26 +2,70%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »